ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations
This series delves into recent advancements in the treatment of advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), focusing on clinical trial findings from FLAURA2, ADAURA, TROPION-Lung01, and HERTHENA-Lung01 and their implications for optimizing patient management and survival outcomes.
EP. 1: Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC
Christine Bestvina, MD, University of Chicago
This episode explores expert insights on the clinical use of osimertinib in the frontline setting for EGFR-mutated NSCLC, the impact of combining osimertinib with platinum-based chemotherapy on progression-free survival (PFS), and the significance of extending PFS by nearly 9 months in patients with advanced NSCLC who are not candidates for curative treatment.
EP. 2: Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA
Christine Bestvina, MD, University of Chicago
This episode delves into expert perspectives on the safety and tolerability of combining osimertinib with chemotherapy in untreated, advanced EGFR-mutated NSCLC, resistance to third-generation EGFR TKIs, the superiority of concurrent versus sequential therapy from the FLAURA2 study, the role of ctDNA in managing additional EGFR mutations, and decision-making in utilizing FLAURA2 for treatment selection.
